Detalles de la búsqueda
1.
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Breast Cancer Res
; 17: 13, 2015 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25633049
2.
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Int J Cancer
; 133(7): 1589-602, 2013 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23553037
3.
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
J Exp Clin Cancer Res
; 42(1): 260, 2023 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37803448
4.
ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.
Mol Cancer
; 9: 291, 2010 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-21059223
5.
Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
Int J Cancer
; 126(4): 885-95, 2010 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19634140
6.
The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Mol Cancer Ther
; 16(1): 102-115, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27980105
7.
Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro.
Anticancer Res
; 26(5A): 3561-6, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17094483
8.
PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Cancer Lett
; 348(1-2): 38-49, 2014 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-24650799
Resultados
1 -
8
de 8
1
Próxima >
>>